Plan and conduct of the study
The results at 5 years (Stott et al., 1976 ) of a Medical Research Council Working Party doubleblind study, planned in 1964, to find out whether 2 years of daily chemotherapy with busulphan or cyclophosphamide, compared with placebo, following surgical removal of bronchial carcinoma would suppress metastases and prolong survival, showed no benefit from either of these cytotoxic agents in the dosage schedules studied. Moreover, there was a high incidence of haematological toxicity to busulphan. All the survivors have now been studied for 15 years and the findings are presented in this report.
Plan and conduct of the study
The plan and conduct of the study were described in detail previously (Medical Research Council, 1971) . In summary, after resection of all intrathoracic bronchial tumour, the patients were allocated at random to receive tablets of busulphan (B series) , cyclophosphamide (C series), or indistinguishable placebos (P series) daily for 2 years. For the first 10 days following operation, all patients received 8 tablets in a single daily dose (B series 4 mg, C series 200 mg). Thereafter they received 6 tablets daily (B series 3 mg, C series 150 mg). However, after about the first year of intake to the study, these maintenance dosages were reduced from 6 to 3 tablets (B series 1.5 mg, C series 75 mg), because of an unexpectedly high incidence of toxicity. The 3 series were very similar with respect to sex, age, type of operation, bronchial site of tumour, histological type of tumour, and whether or not the resected lymphnodes were histologically involved.
Each patient was reported on monthly during the first 3 years, 3-monthly up to 5 years, and annually thereafter. Total leucocyte and platelet counts and haemoglobin concentrations were measured every month during the first 2 years, and thereafter when requested by the clinician. The maintenance dose of tablets was controlled by the clinician from the results of the blood investigations and the dose was reduced if haematological toxicity was suspected.
The study was conducted double-blind. The certified cause of death was obtained from the local centre and was verified from the death entries at the OPCS for all but 2 of the deaths.
It is important to note that as the study was planned in 1964, some of the peri-operative staging procedures which would now be considered desirable were not required as a routine and when done were not necessarily reported. In (Table II) in 131 (54%) of the 243 B, 111 (47%) of the 234 C, and 132 (53%) of the 249 P patients, and had been suspected in a further 25 (10%), 29 (12%), and 28 (11%) respectively. Metastases appeared after similar periods in the 3 series, most of them during the first 5 y, namely in 340 (91 %) of the 374 patients with definite, and in 77 (94%) of the 82 with suspected metastases.
Of the 374 patients (Table III) with definite metastases reported, 352 (94%) died from carcinoma of the bronchus, 18 (5%) from other causes, and the remaining 4 (1%) were still alive at A regression analysis showed that the factor with the greatest influence on survival was whether the resected intrathoracic nodes were histologically involved. Histological type was also important, but only when the nodes were involved. 15 years. The corresponding percentages for patients with suspected metastases were very similar. In comparison, of the 270 patients with no metastases reported, 77 (29%) died from carcinoma of the bronchus, 131 (49%) from other causes, and 62 (23%) were still alive at 15 years. Influence ofpretreatment factors on mortality from bronchial carcinoma The main pretreatment factors related to deaths certified as due to bronchial carcinoma are shown in Table IV . A Cox (1972) model regression analysis using the same factors as in Table IV in addition to treatment series was done to determine which factors had the greatest influence on time of death from bronchial carcinoma. This analysis indicated that the most important factor was whether the patient had histological involvement of the resected intrathoracic nodes. This was confirmed by log-rank test (P<0.00001). Within the group of 336 patients whose nodes were involved, histological type was important, the 226 patients with epidermoid carcinoma surviving significantly longer than the 57 with small cell carcinomas (log-rank test P<0.00001), the 31 with adenocarcinoma (P=0.00002), and all 110 with non-epidermoid carcinomas (P<0.00001). The only other factor to have a significant effect was the site of the involved nodes, the patients with involvement of (a) bronchopulmonary nodes only surviving for longer than those with (b) hilar, but not mediastinal, node involvement and those with (c) mediastinal node involvement (P<0.001 for the trend).
In contrast, within the group of 390 patients without node involvement, there were no significant pretreatment prognostic factors, not even histological type.
The figures for the population as a whole (Table  IV) appear to suggest that segmental resection was as effective as lobectomy. However, such a conclusion would be unwarranted, first because of the small number of patients who had a segmental resection (only 12), and secondly because none of the 12 had intrathoracic nodes involved. Indeed, among the 390 patients without node involvement, 9 (75%) of the 12 who had a segmental resection died of bronchial carcinoma compared with 142 (62%) of the 229 who had a lobectomy, and 93 (62%) of the 149 who had a pneumonectomy.
As would be expected, when deaths from all causes were considered in the regression analysis, age also had an important influence on mortality.
Additional treatment after 5 years During years 6 to 10, 14 patients (6 B, 5 C, 3 P) received treatment for extension or recurrence of their bronchial carcinoma, 3 (1 B, 1 C, 1 P) chemotherapy, 7 (2 B, 3 C, 2 P) radiotherapy, 2 (both B) chemotherapy and radiotherapy, and 2 (1 B, 1 C) surgery. For 13, treatment was for local spread of the disease, and for the 14th for cerebral metastases. During years 11 to 15, 7 patients (2 B, 2 C, 3 P) received treatment, all for local extension of the disease from the primary site; 6 receiving radiotherapy, and 1 (B) chemotherapy.
Other primary neoplasms During the 15 years, 34 patients (12B, 7C, 15P) had at least 1 other primary malignant neoplasm in addition to bronchial carcinoma. In 33 only 1 other site was involved; 9 (4 B, 2 C, 3 P) had tumours of the stomach, 4 (1 B, 1 C, 2 P) of the bladder, 3 (2 B, 1 P) of the skin, 3 (all P) of the rectum, 3 (1 B, 1 C, 1 P) of the colon, 2 (1 C, 1 P) of the prostate, and 1 each of the opposite lung with different histology (C), the larynx (C), the pancreas (P), the cervix (P) and the nasopharynx (P), and 4 (all B) had acute leukaemia. The remaining patient (P) had 2 other primary neoplasms, namely, of the colon and of the prostate. The 4 cases of leukaemia have been reported elsewhere (Stott et al., 1977) .
The time interval between admission to the study and the diagnosis of the second malignancy was 1 to 5y in 10 patients, 6 to 10 in 13 and 11 to 15 in 10 patients. In 1 patient the interval was not known.
Drug toxicity Details of drug toxicity have been reported previously (Stott et al., 1976) . There were important differences between the series with respect to haematological toxicity, which occurred in 177 (73%) of the B patients compared with 86 (37%) of the C, 49 (20%) of the P patients having comparable episodes (Table V) . The commonest mani- (100) 249 (100) festation in all 3 series was thrombocytopenia, and the difference between the B series and each of the other 2 series was highly significant (P<0.0001) for each of the 4 comparisons, namely any haematological toxicity, thrombocytopenia, leucopenia, and anaemia. Nineteen (8%) of the B patients developed pancytopenia compared with only 1 of the C and none of the P patients. All 4 of the B patients in whom acute leukaemia subsequently developed were among the 19 who had pancytopenia. (Leukaemia has been diagnosed subsequent to the 15 years of follow-up in 2 further patients in the B series who will be reported elsewhere.)
Deaths attributable to toxicity In 4 patients (all B) there was evidence that chemotherapy had contributed to death during the first 2 years through marrow depression. A 5th patient (B) died with pancytopenia in the 3rd year and 4 patients (all B) died later from acute leukaemia (Stott et al., 1977) .
Discussion
This trial was planned in 1964 to discover, in a randomised, double-blind, placebo-controlled comparison, whether 2 years of daily treatment with either busulphan or cyclophosphamide would suppress metastases and prolong survival after intended 'curative' resection of bronchial carcinoma. At the time, some investigators had reported favourably on long-term adjuvant chemotherapy with cyclophosphamide (Denk & Karrer, 1961; Poulsen, 1962 Poulsen, , 1963 and on the activity of busulphan against inoperable bronchial carcinoma (Sullivan, 1958) . However, the relative sensitivity of small cell compared with non-small cell carcinomas to chemotherapy (Green et al., 1969; Higgins, 1972; Host, 1973; Selawry, 1974) , and the superiority of pulsed chemotherapy with an interval between each dose (Bergsagel, 1971; Karrer, 1972) and of treatment with combinations of drugs (Carbone et al., 1970; Alberto, 1973; Maurer & Tulloh, 1974; Bunn et al., 1977) (Kron et al., 1982; Spiro & Goldstraw, 1984) .
Published information on the possible prognostic importance of other factors has been conflicting, largely because no attempt is usually made to isolate factors which have an independent effect by means of multiple regression analysis. However, Clee et al. (1984) . in a retrospective study of 337 patients who had a resection for bronchial carcinoma, examined the effects of 14 preoperative and 2 operative variables, and found that a multiple regression analysis identified 4 which had a statistically significant independent effect, viz. a history of weight loss, a history of chest pain developing within 6 months before surgery, the size of the tumour as assessed on the chest radiographs, and the histological cell type. These findings, together with those from the present study, suggest that many of the other factors which have been reported to be of prognostic importance, such as age (Belcher & Anderson, 1965; Higgins et al., 1969) ; sex (Watson & Schottenfeld, 1968) ; type of operation (Bignall et al., 1967; Pool, 1971 ) and site of tumour (Higgins & Beebe, 1967) , are unlikely to have an independent effect, although if all patients, irrespective of the cause of death, are included, age does affect prognosis (Higgins et al., 1969 , and present study).
The surgeons, physicians and pathologists who collaborated in this study are listed in the first report (Medical Research Council, 1971) . Their cooperation is again acknowledged and appreciated.
